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Introduction {#cam4665-sec-0001}
============

An increasing number of studies suggest a role for lipid and glucose metabolism in prostate cancer (PCa) development. Findings from a recent meta‐analysis reported a strong positive association between obesity and risk of advanced prostate cancer [1](#cam4665-bib-0001){ref-type="ref"}, indicating that lifestyle‐related risk factors influence PCa aggressiveness and progression. Nonetheless, epidemiological evidence on the association between other lifestyle‐related risk factors, including dyslipidemia and diabetes, and PCa development and progression remains sparse and inconclusive [2](#cam4665-bib-0002){ref-type="ref"}, [3](#cam4665-bib-0003){ref-type="ref"}, [4](#cam4665-bib-0004){ref-type="ref"}, [5](#cam4665-bib-0005){ref-type="ref"}. Moreover, most of these studies are limited by few cases, short follow‐up time, and lack of power to detect the true associations between the exposures and the outcomes. Biologically, both dyslipidemia and hyperglycemia have been implicated with prostate carcinogenesis. Evidence from experimental studies using in vivo and in vitro models demonstrated that they may induce prostate carcinogenesis by modulating signaling pathways, which promote carcinogenic processes such as cell growth and proliferation, inflammation, oxidative stress, and cell migration [6](#cam4665-bib-0006){ref-type="ref"}, [7](#cam4665-bib-0007){ref-type="ref"}, [8](#cam4665-bib-0008){ref-type="ref"}, [9](#cam4665-bib-0009){ref-type="ref"}, [10](#cam4665-bib-0010){ref-type="ref"}, [11](#cam4665-bib-0011){ref-type="ref"}, [12](#cam4665-bib-0012){ref-type="ref"}, [13](#cam4665-bib-0013){ref-type="ref"}, [14](#cam4665-bib-0014){ref-type="ref"}, [15](#cam4665-bib-0015){ref-type="ref"}.

Based on data in the AMORIS cohort, a large Swedish database with information on over 800,000 men and women, we have previously identified that abnormal serum lipid and glucose profiles may be involved in risk of developing PCa. Our findings showed a positive association between hypertriglyceridemia and PCa risk in hyperglycemic men [16](#cam4665-bib-0016){ref-type="ref"}. Conversely, we found that high‐density lipoprotein and Apolipoprotein A‐1 were inversely associated with PCa risk [17](#cam4665-bib-0017){ref-type="ref"}. Here, we further investigated this by evaluating the association between serum total cholesterol, triglycerides and glucose and PCa risk categories and clinicopathological characteristics (i.e., PSA, Gleason score, and TNM staging) in the updated AMORIS cohort.

Materials and Methods {#cam4665-sec-0002}
=====================

Study design and population {#cam4665-sec-0003}
---------------------------

Detailed description of the AMORIS cohort can be found elsewhere [16](#cam4665-bib-0016){ref-type="ref"}, [18](#cam4665-bib-0018){ref-type="ref"}. Briefly, this database comprises 812,073 Swedish men and women with blood samples sent for laboratory evaluation to the Central Automation Laboratory (CALAB) in Stockholm, Sweden, during the period 1985--1996 [19](#cam4665-bib-0019){ref-type="ref"}, [20](#cam4665-bib-0020){ref-type="ref"}, [21](#cam4665-bib-0021){ref-type="ref"}. Individuals recruited were primarily from the greater Stockholm area, who were either healthy and having laboratory testing as part of a general checkup or outpatients referred for laboratory testing. None of the participants were inpatients at the time of sampling. In the AMORIS cohort, the CALAB database was linked to several Swedish national registries such as the Swedish National Cancer Register, the Hospital Discharge Register, the Cause of Death Register, the consecutive Swedish Censuses during 1970--1990, and the National Register of Emigration using the Swedish 10‐digit personal identity number.

For this study, we specifically focused on the linkage between the AMORIS database and the National Prostate Cancer Register (NPCR), which has been nationwide since 1998 [22](#cam4665-bib-0022){ref-type="ref"}. NPCR was developed to provide data for quality assurance and includes 98% of all newly diagnosed PCa cases registered in the Swedish National Cancer Register [22](#cam4665-bib-0022){ref-type="ref"} to which reporting is mandated. From the NPCR, we extracted information on date of diagnosis, age at diagnosis, TNM stage [19](#cam4665-bib-0019){ref-type="ref"}, Gleason score, serum concentration of PSA at time of diagnosis, and primary treatment given or planned up to 6 months after date of diagnosis. Information on educational level was retrieved from the Population and Housing Census for 1970--1990. Using information from the National Patient Register, we calculated the Charlson comorbidity index which includes 19 diseases, with each disease category assigned a weight. The sum of an individual\'s weights was used to create a score, resulting in four comorbidity levels ranging from no comorbidity to severe comorbidity (0, 1, 2, and ≥3) [23](#cam4665-bib-0023){ref-type="ref"}.

From AMORIS, we selected all men aged 20 and older diagnosed with PCa (and information on their prostate tumor characteristics from 1996 until 31 December 2011), who had baseline levels of serum glucose, total cholesterol, and triglycerides taken from the same health visit [19](#cam4665-bib-0019){ref-type="ref"}. A total of 14,294 men were included in the final analysis. Figure S1 provides an overview of the cohort selection process.

Total cholesterol and triglycerides were measured enzymatically as previously described [24](#cam4665-bib-0024){ref-type="ref"}. Glucose was also measured enzymatically with a glucose oxidase/peroxidase method. All methods were fully automated with automatic calibration and performed at one accredited laboratory [20](#cam4665-bib-0020){ref-type="ref"}.

The primary endpoints for our study are PCa risk categories. These risk categories were defined in accordance with an adapted version of National Comprehensive Cancer Network as low risk (T1‐2, Gleason score 2--6 and PSA \<10 ng/mL), intermediate risk (T1‐2, Gleason score 7 and/or PSA 10 to \<20 ng/mL), high risk (T3 and/or Gleason score 8--10 and/or PSA 20 to \<50 ng/mL), and regionally metastatic tumors (T4 and/or N1 and/or PSA 50--\<100 ng/mL in the absence of distant metastases (M0 or MX)) and distant metastatic tumors (M1 and/or PSA \>100 ng/mL) [22](#cam4665-bib-0022){ref-type="ref"}. We also included the clinicopathological characteristics (PSA levels, Gleason score, T stage) as outcomes. PSA was categorized as \<4 *μ*g/ L, 4--9.9 *μ*g/ L, 10--20 *μ*g/L and \>20 *μ*g/L. Gleason score was defined as low‐grade tumor (Gleason score ≤6 or WHO grade 1), intermediate grade tumor (Gleason score 7 or WHO grade 2) and high‐grade tumor (Gleason score ≥8 or WHO grade 3), while T stage was defined as localized (T1--T2) and advanced (T3--T4).

Statistical analysis {#cam4665-sec-0004}
--------------------

Odds ratios and 95% confidence intervals for the association between serum glucose, total cholesterol and triglycerides and PCa clinicopathological characteristics were calculated using logistic regression. In multivariable analyses, models were adjusted for age at diagnosis, educational level (low, intermediate, high), CCI (0, 1, 2, ≥3), and fasting status (fasting, nonfasting, missing). For each man, we also calculated the interval time between the time from blood analyses and date of PCa diagnosis, which was also included as a covariate in the model. All models were also mutually adjusted for serum glucose, total cholesterol, and triglycerides. Due to the high percentage of cases with missing information on body mass index (BMI) (78.5%), BMI was not included as a covariate in our multivariate model. These missing value indicators were included in the statistical models. We did conduct a sensitivity analysis in the subgroup with information on BMI (*n* = 3073), whereby we adjusted for BMI. Due to the small sample size, statistical significance disappeared, but the directions of the associations virtually remained the same. We also conducted stepwise regression analyses among those with information on BMI to assess the effect of excluding BMI on the multivariate model. The results of our stepwise regression analyses showed that adjusting for BMI had little or no effect on the multivariate model, thus suggesting that BMI may not be an important confounder in this study population. Hence, all results shown are focused on the cohort of 14,294 men. Missing values were assigned to separate categories for education (1.5%) and fasting status (11.0%).

Serum glucose, total cholesterol, and triglycerides levels were analyzed using clinical cut‐offs in accordance with the American Diabetes Association and National Cholesterol Education Programme (NCEP) guidelines[25](#cam4665-bib-0025){ref-type="ref"}, [26](#cam4665-bib-0026){ref-type="ref"}, [27](#cam4665-bib-0027){ref-type="ref"}. Serum glucose levels were categorized as \<5.6 mmol/L, 5.6--6.9 mmol/L, and \>6.9 mmol/L, while serum total cholesterol was classified as \<5.18 mmol/L, 5.18 mmol/L--6.19 mmol/L, and \>6.19 mmol/L and serum triglycerides as \<1.7 mmol/L, 1.7--2.24 mmol/L, and \>2.24 mmol/L. The lowest clinical cut‐offs were selected as the reference category.

Finally, we conducted a sensitivity analysis whereby we excluded men with measurements taken 2 years or less prior to the date of PCa diagnosis to assess possible reverse causation. We also performed a sensitivity analysis whereby we excluded men with nonfasting glucose measurements.

Data management and statistical analyses were conducted with Statistical Analysis Software (SAS) release 9.4 (SAS Institute, Cary, NC).

Results {#cam4665-sec-0005}
=======

Table [1](#cam4665-tbl-0001){ref-type="table-wrap"} illustrates the baseline characteristics of the study population. Mean age at PCa diagnosis was 69 ± 8.0 years. The median levels of glucose, total cholesterol, and triglycerides at baseline were 4.9 mmol/L, 5.8 mmol/L, and 1.2 mmol/L, respectively. Most men had normal glucose (\<5.60 mmol/L) and triglycerides (\<1.7 mmol/L) levels (82.5% and 69.1%, respectively), while at least 75% men had borderline high or high total cholesterol levels with mean time between measurement and PCa diagnosis of 16.7 ± 4.8 years.

###### 

Baseline characteristics of study population

  Characteristics                                                   Total population (*N* = 14294)
  ----------------------------------------------------------------- --------------------------------
  Age at diagnosis (years)                                          
  Mean (SD)                                                         69 (8.0)
  *N* (%)                                                           
  ≤49                                                               95 (0.7)
  50--59                                                            1971 (13.8)
  60--69                                                            6321 (44.2)
  ≥70                                                               5916 (41.4)
  Education                                                         
  High                                                              4427 (31.0)
  Intermediate                                                      5912 (41.2)
  Low                                                               3740 (26.2)
  Missing                                                           215 (1.5)
  Charlson comorbidity index                                        
  0                                                                 10651 (74.5)
  1                                                                 1840 (12.9)
  2                                                                 1104 (7.7)
  ≥3                                                                699 (4.9)
  Glucose (mmol/L)                                                  
  Median (IQR)                                                      4.9 (4.6--5.4)
  *N* (%)                                                           
  \<5.60                                                            11796 (82.5)
  5.6--6.9                                                          2062 (14.4)
  \>6.9                                                             436 (3.1)
  Total cholesterol (mmol/L)                                        
  Median (IQR)                                                      5.8 (5.2--6.5)
  *N*(%)                                                            
  \<5.18                                                            3552 (24.9)
  5.18--6.19                                                        5394 (37.7)
  \>6.19                                                            5348 (37.4)
  Triglycerides (mmol/L)                                            
  Median (IQR)                                                      1.2 (0.9--1.8)
  *N* (%)                                                           
  \<1.70                                                            9878 (69.1)
  1.70--2.24                                                        2199 (15.4)
  ≥2.25                                                             2217 (15.5)
  Fasting status                                                    
  *N* (%)                                                           
  Fasting                                                           8577 (60.0)
  Nonfasting                                                        4143 (29.0)
  Missing/Unknown                                                   1574 (11.0)
  Interval time between measurement and prostate cancer diagnosis   
  Mean (SD)                                                         16.7 (4.8)
  PSA (*μ*g/L)                                                      
  Median (IQR)                                                      9.4 (5.8--20.0)
  *N*(%)                                                            
  \>4                                                               1164 (8.1)
  4.0--9.9                                                          6126 (42.9)
  10.0--20.0                                                        3219 (22.5)
  \>20.0                                                            3351 (23.4)
  Missing                                                           434 (3.0)
  Gleason grade                                                     
  *N* (%)                                                           
  Low                                                               6942 (48.6)
  Intermediate                                                      4789 (33.5)
  High                                                              2320 (16.2)
  Missing                                                           243 (1.7)
  Clinical stage                                                    
  *N* (%)                                                           
  T1                                                                6797 (47.6)
  T2                                                                4290 (30.0)
  T3                                                                2496 (17.5)
  T4                                                                319 (3.2)
  Missing                                                           392 (2.7)
  N0                                                                1502 (10.5)
  N1                                                                292 (1.0)
  Missing/NX                                                        12500 (87.5)
  M0                                                                4665 (32.6)
  M1                                                                867 (6.1)
  Missing/MX                                                        8762 (61.3)
  Risk categories                                                   
  *N* (%)                                                           
  Localized                                                         
  Low risk                                                          4472 (31.3)
  Intermediate risk                                                 4032 (28.2)
  High risk                                                         3258 (22.8)
  Regional/distant metastatic                                       2187 (15.3)
  Missing                                                           345 (2.4)

John Wiley & Sons, Ltd

Men with glucose in the prediabetic range (5.6--6.9 mmol/L) had a greater odds of high risk and metastatic cancer, as compared to normoglycemic men (OR: 1.13; 95% CI: 0.98--1.30 and OR: 1.21; 95% CI: 1.04--1.42 for high risk and metastatic PCa, respectively) (Table [2](#cam4665-tbl-0002){ref-type="table-wrap"}). Triglycerides were positively associated with intermediate risk localized PCa for the highest versus the lowest subgroup (OR: 1.17; 95% CI: 1.03--1.34). Positive but nonstatistically significant associations between hypertriglyceridemia and high risk and metastatic PCa were also observed. When considering total cholesterol, there was no evidence to suggest any differences in any of the outcomes studies based on serum total cholesterol levels.

###### 

Odds ratios (OR) and 95% CI for risk categories (intermediate‐risk localized/low‐risk localized, high‐risk localized/low‐risk localized and metastatic/low‐risk localized) by baseline levels of serum glucose, total cholesterol, and triglycerides

                                                    Glucose (mmol/L)[a](#cam4665-note-0004){ref-type="fn"}   *P* for trend       Total cholesterol (mmol/L)   *P* for trend   Triglycerides (mmol/ L)   *P* for trend                                                                                        
  ------------------------------------------------- -------------------------------------------------------- ------------------- ---------------------------- --------------- ------------------------- ------------------- ------------------- ------- ------------ ------------------- ------------------- -------
  Low risk (Reference level for outcome studied)                                                                                                                                                                                                                                                             
  *N* = 4472                                        3794                                                     558                 120                                          1189                      1689                1594                        3152         690                 630                 
  Intermediate risk                                                                                                                                                                                                                                                                                          
  *N* = 4032                                        3359                                                     566                 107                                          1029                      1527                1476                        2784         603                 645                 
  Age‐adjusted OR (95% CI)                          1.00 (Ref)                                               1.08 (0.95--1.23)   0.94 (0.72--1.22)            0.601           1.00 (Ref)                0.97 (0.87--1.08)   0.96 (0.86--1.07)   0.469   1.00 (Ref)   0.99 (0.87--1.11)   1.17 (1.03--1.32)   0.030
  Multivariable adjusted OR (95% CI)                1.00 (Ref)                                               1.07 (0.94--1.21)   0.90 (0.69--1.19)            0.864           1.00 (Ref)                0.96 (0.86--1.07)   0.93 (0.83--1.05)   0.228   1.00 (Ref)   0.99 (0.88--1.12)   1.17 (1.03--1.34)   0.037
  High risk                                                                                                                                                                                                                                                                                                  
  *N* = 3258                                        2630                                                     523                 105                                          752                       1216                1290                        2216         529                 513                 
  Age--adjusted OR (95% CI)                         1.00 (Ref)                                               1.23 (1.07--1.41)   1.09 (0.82--1.44)            0.016           1.00 (Ref)                1.00 (0.88--1.13)   1.06 (0.94--1.20)   0.287   1.00 (Ref)   1.09 (0.96--1.25)   1.20 (1.05--1.37)   0.006
  Multivariable adjusted OR (95% CI)                1.00 (Ref)                                               1.13 (0.98--1.30)   0.93 (0.69--1.24)            0.394           1.00 (Ref)                0.97 (0.85--1.10)   0.99 (0.87--1.13)   0.935   1.00 (Ref)   1.05 (0.92--1.21)   1.14 (0.98--1.31)   0.083
  Regional/distant metastatic                                                                                                                                                                                                                                                                                
  *N* = 2187                                        1726                                                     371                 90                                           506                       822                 859                         1487         323                 377                 
  Age‐adjusted OR (95% CI)                          1.00 (Ref)                                               1.32 (1.14--1.54)   1.43 (1.06--1.92)            \<0.001         1.00 (Ref)                1.01 (0.88--1.17)   1.05 (0.91--1.21)   0.449   1.00 (Ref)   0.97 (0.83--1.13)   1.31 (1.12--1.52)   0.003
  Multivariable adjusted OR (95% CI)                1.00 (Ref)                                               1.21 (1.04--1.42)   1.10 (0.80--1.49)            0.048           1.00 (Ref)                0.97 (0.83--1.12)   0.95 (0.82--1.10)   0.515   1.00 (Ref)   0.92 (0.78--1.07)   1.17 (0.99--1.37)   0.172

Multivariable models‐adjusted for age educational level, Charlson comorbidity index, serum glucose, total cholesterol, triglycerides, fasting status, time between measurement, and prostate cancer diagnosis.

Ref, Reference.

Not adjusted for Charlson comorbidity index.

John Wiley & Sons, Ltd

When studying PSA as an outcome, we observed that a greater proportion of men with glucose levels \>6.90 mmol/L had PSA \<4 *μ*g/L (OR: 1.43; 95% CI: 1.01--1.45), compared to PSA levels of 4.0--9.9 *μ*g/L. There was also a positive association between glucose levels of 5.6--6.9 mmol/L and PSA levels \>20 *μ*g/L compared to PSA levels of 4.0--9.9 *μ*g/L (OR: 1.28; 95% CI: 1.13--1.45) (Table [3](#cam4665-tbl-0003){ref-type="table-wrap"}). Moreover, we found a positive association between triglycerides ≥2.25 mmol/L and PSA levels \>20 *μ*g/L (OR: 1.17; 95% CI: 1.03--1.34), as compared to PSA levels of 4.0--9.9 *μ*g/L.

###### 

Odds ratio and 95% CI for the association between serum lipids (total cholesterol and triglycerides) and glucose levels and PSA levels and Gleason score

                                                                Glucose (mmol/L)[a](#cam4665-note-0007){ref-type="fn"}   *P* for trend       Total cholesterol (mmol/L)   *P* for trend   Triglycerides (mmol/L)   *P* for trend                                                                                        
  ------------------------------------------------------------- -------------------------------------------------------- ------------------- ---------------------------- --------------- ------------------------ ------------------- ------------------- ------- ------------ ------------------- ------------------- -------
  PSA \<4 versus 4.0--9.9(*μ*g/L)                               971                                                      152                 41                                           329                      448                 387                         816          188                 160                 
  *N* = 6126                                                                                                                                                                                                                                                                                                            
  Age‐adjusted OR (95% CI)                                      1.00 (Ref)                                               1.06 (0.88--1.28)   1.41 (1.00--2.01)            0.081           1.00 (Ref)               0.99 (0.86--1.01)   0.84 (0.99--1.16)   0.105   1.00 (Ref)   1.06 (0.89--1.26)   0.94 (0.78--1.13)   0.698
  Multivariable adjusted OR (95% CI)                            1.00 (Ref)                                               1.08 (0.89--1.30)   1.43 (1.01--2.05)            0.071           1.00 (Ref)               0.99 (0.85--1.16    0.88 (0.75--1.05)   0.130   1.00 (Ref)   1.09 (0.91--1.30)   0.98 (0.80--1.18)   0.900
  PSA 4.0--9.9 (*μ*g/L) (Reference level for outcome studied)                                                                                                                                                                                                                                                           
  *N* = 1164                                                    5184                                                     781                 161                                          1591                     2279                2256                        4292         937                 897                 
  PSA 10.0--20.0 versus 4.0--9.9(*μ*g/L)                                                                                                                                                                                                                                                                                
  *N* = 3219                                                    2684                                                     442                 93                                           749                      1253                1217                        2205         507                 507                 
  Age‐adjusted OR (95% CI)                                      1.00 (Ref)                                               1.05 (0.92--1.19)   1.04 (0.80--1.35)            0.485           1.00 (Ref)               1.09 (0.98--1.22)   1.03 (0.92--1.16)   0.754   1.00 (Ref)   1.05 (0.93--1.19)   1.13 (1.00--1.28)   0.044
  Multivariable adjusted OR (95% CI)                            1.00 (Ref)                                               0.98 (0.85--1.11)   0.91 (0. 69--1.18)           0.450           1.00 (Ref)               1.05 (0.94--1.18)   0.98 (0.87--1.10)   0.576   1.00 (Ref)   1.04 (0.92--1.18)   1.11 (0.97--1.26)   0.119
  PSA \>20.0 versus 4.0--9.9(*μ*g/ L)                                                                                                                                                                                                                                                                                   
  *N* = 3351                                                    2625                                                     595                 131                                          789                      1232                1330                        2284         505                 562                 
  Age‐adjusted OR (95% CI)                                      1.00 (Ref)                                               1.41 (1.25--1.60)   1.41 (1.10--1.81)            \<0.001         1.00 (Ref)               0.97 (0.86--1.09)   1.00 (0.89--1.13)   0.889   1.00 (Ref)   1.01 (0.89--1.14)   1.22 (1.08--1.38)   0.004
  Multivariable adjusted OR (95% CI)                            1.00 (Ref)                                               1.28 (1.13--1.45)   1.06 (0.82--1.37)            0.004           1.00 (Ref)               0.92 (0.82--1.04)   0.91 (0.81--1.03)   0.153   1.00 (Ref)   0.98 (0.86--1.11)   1.17 (1.03--1.34)   0.040
  Gleason ≤6 (Reference level for outcome studied)                                                                                                                                                                                                                                                                      
  *N* = 6942                                                    5859                                                     896                 187                                          1175                     2637                2530                        4841         1059                1042                
  Gleason 7 versus ≤6                                                                                                                                                                                                                                                                                                   
  *N* = 4789                                                    3913                                                     727                 149                                          1195                     1795                1799                        3314         733                 742                 
  Age‐adjusted OR (95% CI)                                      1.00 (Ref)                                               1.14 (1.01--1.27)   1.04 (0.81--1.33)            0.076           1.00 (Ref)               0.95 (0.86--1.06)   0.97 (0.87--1.07)   0.588   1.00 (Ref)   1.02 (0.91--1.14)   1.06 (0.95--1.18)   0.319
  Multivariable adjusted OR (95% CI)                            1.00 (Ref)                                               1.18 (1.05--1.33)   1.09 (0.84--1.40)            0.017           1.00 (Ref)               0.97 (0.87--1.07)   0.98 (0.88--1.08)   0.690   1.00 (Ref)   1.03 (0.92--1.17)   1.07 (0.95--1.20)   0.264
  Gleason ≥8 versus ≤6                                                                                                                                                                                                                                                                                                  
  *N* = 2320                                                    1830                                                     398                 92                                           514                      869                 937                         1557         367                 396                 
  Age‐adjusted OR (95% CI)                                      1.00 (Ref)                                               1.26 (1.09--1.46)   1.39 (1.03--1.87)            \<0.001         1.00 (Ref)               1.06 (0.92--1.22)   1.14 (1.00--1.31)   0.052   1.00 (Ref)   1.10 (0.95--1.28)   1.25 (1.09--1.45)   0.002
  Multivariable adjusted OR (95% CI)                            1.00 (Ref)                                               1.24 (1.07--1.44)   1.37 (1.02--1.87)            0.001           1.00 (Ref)               1.05 (0.91--1.21)   1.11 (0.96--1.28)   0.156   1.00 (Ref)   1.06 (0.92--1.24)   1.17 (1.01--1.37)   0.040
  T1--T2 (Reference level for outcome studied)                                                                                                                                                                                                                                                                          
  *N* = 11087                                                   9256                                                     1525                306                                          2814                     4197                4076                        7725         1681                1681                
  T3--T4 versus T1--T2                                                                                                                                                                                                                                                                                                  
  *N* = 2815                                                    2226                                                     474                 115                                          656                      1040                1119                        1888         455                 472                 
  Age‐adjusted OR (95% CI)                                      1.00 (Ref)                                               1.21 (1.08--1.36)   1.42 (1.13--1.77)            \<0.001         1.00 (Ref)               0.98 (0.88--1.10)   1.04 (0.94--1.17)   0.367   1.00 (Ref)   1.12 (0.99--1.26)   1.18 (1.05--1.33)   0.002
  Multivariable adjusted OR (95% CI)                            1.00 (Ref)                                               1.12 (0.99--1.26)   1.20 (0.96--1.52)            0.022           1.00 (Ref)               0.95 (0.85--1.06)   0.98 (0.88--1.10)   0.860   1.00 (Ref)   1.08 (0.96--1.22)   1.12 (0.99--1.27)   0.046

Multivariable models--adjusted for age, educational level, Charlson comorbidity index, serum glucose, total cholesterol, triglycerides, fasting status, time between measurement, and prostate cancer diagnosis.

Ref, Reference.

Not adjusted for Charlson comorbidity index.

John Wiley & Sons, Ltd

For Gleason score, we found a positive association between glucose levels of 5.6--6.9 mmol/L and risk of intermediate‐grade (OR: 1.18; 95% CI: 1.05--1.33) and high‐grade PCa (OR: 1.24; 95% CI: 1.07--1.44) (Table [3](#cam4665-tbl-0003){ref-type="table-wrap"}). Compared to men with glucose \<5.6 mmol/L, there was also an increased odds of high‐risk PCa among men with glucose levels in the diabetic range (\>6.9 mmol/L) (OR: 1.37; 95%: 1.02--1.87). Hypertriglyceridemia was positively associated with high‐grade PCa (OR: 1.17; 95% CI: 1.01--1.37), but the odds of intermediate grade PCa did not appear to be different by triglycerides levels. Although neither glucose nor triglycerides had a statistically significant association with stage of PCa, there was an observed trend toward increased odds of T3--T4 PCa with increasing glucose and triglycerides levels (P for trend: 0.022 and 0.046, respectively).

The exclusion of 21 men with measurements taken less than 2 years prior to PCa diagnosis did not result in changes in the findings (Table S2 and S3). When we restricted our analyses to men with fasting glucose measurements, the direction of the associations remained virtually unchanged (Table S4).

Discussion {#cam4665-sec-0006}
==========

In this study, we found evidence suggesting an independent positive association between serum glucose levels and higher grade (Gleason score 7 or ≥8) and advanced PCa (T3--T4, metastatic PCa). Similarly, men with hypertriglyceridemia (≥2.25 mmol/L) had increased odds of higher grade or more advanced PCa. When PSA was taken into account, we observed that men with glucose levels in the diabetic range (\>6.9 mmol/L) had greater odds of having PSA levels \<4 *μ*g/L, while those with glucose levels in the prediabetic range (5.6--6.9 mmol/L) had greater odds of having PSA \>20 *μ*g/L. Men with hypertriglyceridemia (≥2.25 mmol/L) also had increased odds of PSA \>20 *μ*g/L. There was, however, no evidence to suggest that the odds of any of the outcomes studied varied by total cholesterol levels.

Glucose {#cam4665-sec-0007}
-------

Hyperglycemia has been positively associated with cancers such as pancreatic, breast, and colorectal cancer [28](#cam4665-bib-0028){ref-type="ref"}, [29](#cam4665-bib-0029){ref-type="ref"}. However, its link with prostate carcinogenesis is conflicting. Consistent with our findings, four other studies found evidence of higher risk of more aggressive or advanced PCa among men with abnormal glucose levels with the association being nonsignificant in two of the studies [3](#cam4665-bib-0003){ref-type="ref"}, [4](#cam4665-bib-0004){ref-type="ref"}, [30](#cam4665-bib-0030){ref-type="ref"}, [31](#cam4665-bib-0031){ref-type="ref"}, [32](#cam4665-bib-0032){ref-type="ref"}. Conversely, several other studies reported a protective effect of hyperglycemia or diabetes against higher grade or more advanced PCa [33](#cam4665-bib-0033){ref-type="ref"}, [34](#cam4665-bib-0034){ref-type="ref"}, [35](#cam4665-bib-0035){ref-type="ref"}, [36](#cam4665-bib-0036){ref-type="ref"}, [37](#cam4665-bib-0037){ref-type="ref"}, [38](#cam4665-bib-0038){ref-type="ref"}. The observed positive association reported by our study may be explained by several underlying biological mechanisms. For several decades, glucose has been documented as an important source of energy for rapid tumor cell proliferation [39](#cam4665-bib-0039){ref-type="ref"}, [40](#cam4665-bib-0040){ref-type="ref"}. Evidence from clinical and genetic studies have also linked the hyperglycemic environment to carcinogenic processes such as apoptosis, oxidative stress, DNA damage, and chronic inflammation, which may drive the aggressiveness and progression of cancer (Fig. [1](#cam4665-fig-0001){ref-type="fig"}) [11](#cam4665-bib-0011){ref-type="ref"}, [12](#cam4665-bib-0012){ref-type="ref"}, [13](#cam4665-bib-0013){ref-type="ref"}, [14](#cam4665-bib-0014){ref-type="ref"}, [40](#cam4665-bib-0040){ref-type="ref"}, [41](#cam4665-bib-0041){ref-type="ref"}. For instance, one mice study found that translation of the glycolytic enzyme hexokinase 2 (HK2) was increased in PCa cells due to loss of Pten and p53, which help to prevent cells from growing uncontrollably [11](#cam4665-bib-0011){ref-type="ref"}. GLUT12, an important protein in the glycolytic pathway, was also observed to be highly expressed by PCacells and may potentially help to facilitate the high energy needs of tumor cells [12](#cam4665-bib-0012){ref-type="ref"}. Other metabolic changes such as hyperinsulinemia, increased level of bioavailable IGF 1, and increased production of advanced glycation end products (AGE), which occur in response to a hyperglycemic environment, have also been linked to increased proliferation of cancer cells and poorer cancer outcomes [42](#cam4665-bib-0042){ref-type="ref"}, [43](#cam4665-bib-0043){ref-type="ref"}.

![Schematic representation of carcinogenic processes suggested to be associated with hyperglycemia and dyslipidemia.](CAM4-5-1307-g001){#cam4665-fig-0001}

Furthermore, the observed positive association between glucose and more aggressive or advanced PCa persisted even after correcting for the potential confounding effects of BMI. Unlike most of the observational studies which examined the link between diabetes and PCa outcomes, we focused on serum glucose which has been suggested to be more sensitive than diabetes for accurately determining the relationship between glucose regulation and disease outcomes [44](#cam4665-bib-0044){ref-type="ref"}. Nevertheless, in our study, we lacked information on duration of glucose aberrations. Prolonged glucose impairment has been reported to cause destruction of the Leydig cells, thereby, resulting in lower testosterone levels and potentially lowering the risk of worse outcomes [40](#cam4665-bib-0040){ref-type="ref"}, [45](#cam4665-bib-0045){ref-type="ref"}, [46](#cam4665-bib-0046){ref-type="ref"}, [47](#cam4665-bib-0047){ref-type="ref"}, [48](#cam4665-bib-0048){ref-type="ref"}. Nonetheless, evidence linking lower testosterone to reduced risk of worse PCa outcomes remains conflicting [46](#cam4665-bib-0046){ref-type="ref"}, [47](#cam4665-bib-0047){ref-type="ref"}, [48](#cam4665-bib-0048){ref-type="ref"}.

Similar to our study, one recent study reported higher PSA levels among prediabetic men [49](#cam4665-bib-0049){ref-type="ref"}. In line with our findings, several studies also reported that diabetes or glucose in the diabetic range was associated with lower PSA levels [50](#cam4665-bib-0050){ref-type="ref"}, [51](#cam4665-bib-0051){ref-type="ref"}, [52](#cam4665-bib-0052){ref-type="ref"}, [53](#cam4665-bib-0053){ref-type="ref"}, [54](#cam4665-bib-0054){ref-type="ref"}. Overall, our findings suggest that the effect of glucose levels in the prediabetic phase on PSA levels may be different from the diabetic phase. The potential mechanism through which prediabetes or impaired glucose tolerance may affect PSA levels is unknown. It is possible that in the prediabetic spectrum, the hormonal milieu characterized by hyperinsulinemia or higher IGF‐1 activity may play a role [41](#cam4665-bib-0041){ref-type="ref"}. With regard to men with glucose in the diabetic range, the underlying mechanisms which may partly explain the observed lower PSA levels involve reduction in testosterone levels and insulin‐growth factor‐1 bioactivity, resulting from hypoinsulinemia in the long term, and the use of metformin, a potential antineoplastic treatment [40](#cam4665-bib-0040){ref-type="ref"}, [41](#cam4665-bib-0041){ref-type="ref"}, [55](#cam4665-bib-0055){ref-type="ref"}, [56](#cam4665-bib-0056){ref-type="ref"}, [57](#cam4665-bib-0057){ref-type="ref"}. Additionally, obesity, which is common among men with abnormal glucose levels, may also have contributed to the observed lower PSA levels due to PSA hemodilution [40](#cam4665-bib-0040){ref-type="ref"}, [52](#cam4665-bib-0052){ref-type="ref"}, [58](#cam4665-bib-0058){ref-type="ref"}. However, in our subgroup analyses involving men with information on BMI, adjusting for BMI had minimal or no effect on the multivariate model.

Interestingly, we also found that although among men with glucose in the diabetic range (\>6.9 mmol/L) had lower PSA levels, they had a greater odds of high‐grade or more advanced PCa. This finding may be partly due to the fact that men with PSA \<4 *μ*g/L are not likely to be biopsied and may therefore be diagnosed in the symptomatic stage when the cancer is more aggressive or advanced. These results are also in line with other studies indicating that men with low‐PSA producing cancers tend to develop very poorly differentiated or highly tumorigenic castration‐resistant PCa cells [59](#cam4665-bib-0059){ref-type="ref"}, [60](#cam4665-bib-0060){ref-type="ref"}, [61](#cam4665-bib-0061){ref-type="ref"}.

Total cholesterol and triglycerides {#cam4665-sec-0008}
-----------------------------------

Four prospective studies found positive associations between total cholesterol and higher grade or more advanced PCa [5](#cam4665-bib-0005){ref-type="ref"}, [62](#cam4665-bib-0062){ref-type="ref"}, [63](#cam4665-bib-0063){ref-type="ref"}, [64](#cam4665-bib-0064){ref-type="ref"}, [65](#cam4665-bib-0065){ref-type="ref"}. Comparable to our study, the effect was positive, but statistically significant in two of these studies [5](#cam4665-bib-0005){ref-type="ref"}, [65](#cam4665-bib-0065){ref-type="ref"}. Upon adjustment for age, we observed that the statistical significant ORs disappeared, which is consistent with the well‐established view that age is a shared risk factor for both hypercholesterolemia and cancer [45](#cam4665-bib-0045){ref-type="ref"}, [66](#cam4665-bib-0066){ref-type="ref"}, [67](#cam4665-bib-0067){ref-type="ref"}.

Previously, we provided evidence supporting a potential role for lipid metabolism in PCa development [16](#cam4665-bib-0016){ref-type="ref"}, [17](#cam4665-bib-0017){ref-type="ref"}. Here, we provided further evidence showing that triglycerides may influence the aggressiveness and severity of PCa. Except for one small Japanese study, most epidemiological studies did not report a link between triglycerides and PCa prognostic outcomes [2](#cam4665-bib-0002){ref-type="ref"}. However, experimental studies using in vitro models, have shown that triglyceride‐rich remnant like particles induce carcinogenesis by upregulating cell signaling pathways, such as the MEK/ERK and Akt pathways, involved in controlling cell growth and proliferation, apoptosis, cell cycle arrest, and lipid biosynthesis (Fig [1](#cam4665-fig-0001){ref-type="fig"}) [7](#cam4665-bib-0007){ref-type="ref"}, [8](#cam4665-bib-0008){ref-type="ref"}, [68](#cam4665-bib-0068){ref-type="ref"}.

Consistent with results from previous studies, total cholesterol did not appear to have an influence on PSA levels [69](#cam4665-bib-0069){ref-type="ref"}, [70](#cam4665-bib-0070){ref-type="ref"}. In contrast to our findings, one study including 6774 Chinese men, reported an inverse association between triglycerides and PSA levels [71](#cam4665-bib-0071){ref-type="ref"}. Two other studies, however, did not find any association between triglycerides and PSA [69](#cam4665-bib-0069){ref-type="ref"}, [70](#cam4665-bib-0070){ref-type="ref"}. Further studies are needed to assess the relation between these lipids and PSA levels in men with PCa, as most studies to date involve healthy men from a relatively low‐risk Asian population.

Strengths and limitations {#cam4665-sec-0009}
-------------------------

This is one of the largest prospective studies to investigate the relation between glucose and lipid metabolism and clinicopathological characteristics of PCa. Our study population was also selected from an almost complete population‐based PCa register. Another strength of our study is the use of prediagnostic exposure measurements, which were all measured at a central laboratory. This enabled us to assess relations between the exposures and outcomes temporally and minimized the potential influence of reverse causation. Moreover, the results of our sensitivity analyses did not indicate any evidence of reverse causation.

PCa is a slow‐progressing cancer [72](#cam4665-bib-0072){ref-type="ref"} with a long induction period estimated at 6--13 years by some studies [73](#cam4665-bib-0073){ref-type="ref"}. In this study, the relatively long time of 16.7 years between exposure measurement and PCa diagnosis, which may reflect the induction period between the exposures and PCa, can also be considered as a strength. However, we only used a single baseline exposure measurement, precluding consideration of the effect of longitudinal changes in exposure level over time [33](#cam4665-bib-0033){ref-type="ref"}, [37](#cam4665-bib-0037){ref-type="ref"}. Further studies using repeated measurements are therefore warranted to account for the potential effect of this limitation. Our study also lacks information on participants' diabetic status and history of use of metformin and/or statin, so that exposure misclassification may have occurred. However, any such misclassification would be nondifferential since we used prediagnostic baseline exposure measurements. We did not have information on life‐style‐related factors such as smoking status and dietary history. Nonetheless, existing evidence does not appear to substantiate a link between the afore‐mentioned lifestyle risk factors and poorer PCa outcomes [1](#cam4665-bib-0001){ref-type="ref"}. Based on the results of our sensitivity analyses, the lack of information on fasting status for some men did not appear to influence our results. Finally, we lack follow‐up information on the clinicopathological characteristics of PCa such as PSA, and therefore, could not evaluate the association between the studied serum biomarkers and PCa biochemical recurrence or PCa progression.

Conclusion {#cam4665-sec-0010}
==========

Our findings suggest that the potential influence of glucose on PSA levels may vary as one progress from the prediabetic phase to the diabetic phase. Interestingly, though men in both the intermediate and highest glucose subgroups had poorer PCa outcomes. These findings may have important clinical implications for PCa detection and treatment, particularly among men with high glucose and low PSA levels, as previous evidence have shown that low PSA level is also concomitant with poorer PCa survival [61](#cam4665-bib-0061){ref-type="ref"}. Overall, our findings further support a potential role for the lipid and glucose metabolism in prostate carcinogenesis.
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**Table S1.** Odds ratios (OR) and 95% CI for prostate cancer risk categories by baseline levels of serum glucose, total cholesterol, and triglycerides for men with measurements more than 2 years prior to diagnosis.

**Table S2**. Odds ratio and 95% CI for the association between serum lipids (total cholesterol and triglycerides) and glucose levels and PSA levels and Gleason score.
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